Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-607-8 | CAS number: 97-77-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Disulfiram was widely used (approx. since 1950) as a drug for treatment of alcoholismis, usually administered p.o. in daily doses of 100 - 400 mg. It causes a blockade of the enzyme aldehyde dehydrogenase with consequently increasing levels of acetaldehyde upon ethanol consumption. The unpleasant clinical signs are known as Disulfiram-ethanol reaction (DER). Disulfiram also blocks the enzymatic degradation of dopamine by inhibition of dopamine b-hydroxylase (DBH). This effect might be used in the pharmacotherapy for the treatment of cocaine dependence.
Additional information
Adverse effects of disulfiram as well as contraindications are well investigated, as disulfiram was used for decades as a therapeutic drug against alcoholism. In recent publications (reviewed by Kampman, 2009) the pharmacological safety of disulfiram was evaluated again, as it was shown to have the potential to treat cocaine dependence. Whereas aldehyde dehydrogenase is the primary target in treating alcoholism, human laboratory, genetic, and preclinical animal studies indicate that its beneficial effects on cocaine use result from the inhibition of dopamine b-hydroxylase (Gaval-Cruz, 2009).
Peachey (1981) summarized four areas of concern associated with repeated disulfiram application:
Medical complications during disulfiram-ethanol reaction (DER)
Myocardial infarction, shock, and death can occur during the DER. Cerebrovascular haemorrhage and infarction, causing loss of consciousness during the DER followed by death after several days, are also reported. Although most fatal DERs have been associated with excessive dosages of disulfiram (> 1500 mg daily) followed by consumption of large amounts of ethanol, deaths have also been reported with therapeutic disulfiram dosages and relatively small amounts of ethanol. Reversible electrocardiographic changes are recorded during the DER.
Toxicity associated with disulfiram administration in humans
Disulfiram and its metabolite diethyldithiocarbamate (DDC) inhibit dopamine-b-hydroxylase (DBH) causing increased dopamine levels and decreased norepinephrine levels in the brain and other tissues. Drowsiness, lethargy, disturbed sexual function, and neuropsychological dysfunction occur as a result of the DBH inhibition. More serious behavioural changes include psychosis and acute encephalopathy which occur particularly in individuals with low cerebral spinal fluid DBH activity or low pretreatment levels of platelet monoamine oxidase and amine oxidase and high levels of red cell catechol-O-methyltransferase. Patients with a diagnosis of depression or borderline schizophrenia may manifest more psychopathology while taking disulfiram. The development of neuropathy, muscle weakness, and motor incoordination are the result of CS2-induced toxicity during disulfiram treatment. In addition, disulfiram may cause hepatotoxicity, atherosclerosis, and increased blood pressure. Limb anomalies have been reported in infants born on disulfiram-treated alcoholic mothers.
Drug-drug interactions
Disulfiram inhibits the metabolism of other drugs including antipyrine, phenytoin, warfarin, isoniazid, rifampin, diazepam, and chlordiazepoxide causing increased blood levels of these drugs. It is noteworthy that a similar reaction does not occur with short- and intermediate acting benzodiazepines. The simultaneous administration of disulfiram with warfarin may result in prolongation of the prothrombin time with subsequent haemorrhage. Similarly, cumulative toxicity to phenytoin has been reported in alcoholics receiving disulfiram. On the other hand, with cessation of disulfiram administration, dosages of the other drugs may need to be adjusted downward. Diazepam induces the intensity of the DER, while amitriptyline enhances DER.
Toxicity due to acetaldehyde
Blood acetaldehyde levels are raised appreciably in disulfiram-treated alcoholics following the ingestion of relatively small amounts of ethanol. It is possible that alcoholics who receive disulfiram and who continue to drink may experience some degree of acetaldehyde-induced cardiotoxicity and/or hepatotoxicity.
Clinical cases are published, where delirium-associated neurotoxic effects are described. However, neurotoxic effects occurred upon combined exposure to disulfiram and ethanol (Mirsal, 2005).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.